Clinical Trials Directory

Trials / Completed

CompletedNCT02683928

To Assess the Safety and Activity of GBR 830, Compared to Placebo, in Adults With Moderate-to-severe Atopic Dermatitis

A Phase IIa, Double-Blind, Randomised, Placebo-controlled, Exploratory Study to Evaluate the Safety, Biological Activity and Pharmacokinetics of GBR 830 in Adults With Moderate-to-Severe Atopic Dermatitis

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
64 (actual)
Sponsor
Ichnos Sciences SA · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the effect of GBR 830 on biomarkers in atopic dermatitis to enable further studies in this indication.

Conditions

Interventions

TypeNameDescription
BIOLOGICALGBR 830
BIOLOGICALPlacebo

Timeline

Start date
2016-03-01
Primary completion
2017-06-01
Completion
2017-06-01
First posted
2016-02-17
Last updated
2020-05-18
Results posted
2020-05-18

Locations

17 sites across 2 countries: United States, Canada

Source: ClinicalTrials.gov record NCT02683928. Inclusion in this directory is not an endorsement.